Evogene (EVGN) Competitors $1.21 -0.02 (-1.63%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.41%) As of 08/8/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, TOMZ, ENFY, SNES, GURE, CNEY, NITO, BSLK, HGAS, and TANHShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Senestech (SNES), Gulf Resources (GURE), CN Energy Group. (CNEY), N2OFF (NITO), Bolt Projects (BSLK), Global Gas (HGAS), and Tantech (TANH). Evogene vs. Its Competitors Carisma Therapeutics TOMI Environmental Solutions Enlightify Senestech Gulf Resources CN Energy Group. N2OFF Bolt Projects Global Gas Tantech Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Do institutionals and insiders hold more shares of EVGN or CARM? 10.4% of Evogene shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer EVGN or CARM? Evogene presently has a consensus price target of $3.50, suggesting a potential upside of 189.26%. Carisma Therapeutics has a consensus price target of $1.93, suggesting a potential upside of 612.96%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71 Does the media prefer EVGN or CARM? In the previous week, Carisma Therapeutics had 1 more articles in the media than Evogene. MarketBeat recorded 1 mentions for Carisma Therapeutics and 0 mentions for Evogene. Evogene's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score. Company Overall Sentiment Evogene Neutral Carisma Therapeutics Neutral Which has better valuation and earnings, EVGN or CARM? Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvogene$8.51M0.76-$16.49M-$2.69-0.45Carisma Therapeutics$19.63M0.57-$60.48M-$1.56-0.17 Which has more risk and volatility, EVGN or CARM? Evogene has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Is EVGN or CARM more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Evogene-224.82% -102.40% -39.19% Carisma Therapeutics -254.28%N/A -137.38% SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.60M$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-0.4516.9029.7524.84Price / Sales0.76313.57449.1298.65Price / CashN/A41.8536.4258.36Price / Book0.447.318.185.64Net Income-$16.49M-$54.43M$3.26B$265.68M7 Day Performance4.31%0.00%6.88%4.95%1 Month Performance-18.79%1.33%1.00%0.83%1 Year Performance-70.92%8.64%28.85%22.18% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.2102 of 5 stars$1.21-1.6%$3.50+189.3%-70.1%$6.60M$8.51M-0.45140Gap UpCARMCarisma Therapeutics2.3501 of 5 stars$0.31-1.1%$1.93+525.0%-70.0%$13.02M$19.63M-0.2020Analyst ForecastGap DownTOMZTOMI Environmental Solutions3.1307 of 5 stars$0.97-0.2%$3.50+260.4%+47.8%$19.49M$7.74M-5.7120ENFYEnlightifyN/A$0.93+2.7%N/AN/A$14.35M$95.85M-0.75424SNESSenestech2.3875 of 5 stars$6.15+17.1%$10.00+62.6%+11.4%$11.80M$1.86M-0.8030News CoverageEarnings ReportHigh Trading VolumeGUREGulf Resources0.4709 of 5 stars$0.66+1.5%N/A-40.4%$8.64M$7.66M-0.12420Gap UpCNEYCN Energy Group.0.5991 of 5 stars$2.10-0.5%N/A-70.7%$6.35M$50.96M0.00160NITON2OFF0.7225 of 5 stars$0.23+4.5%N/A-30.6%$5.93M$210K0.002Upcoming EarningsGap UpBSLKBolt ProjectsN/A$2.46+1.7%N/AN/A$4.99M$1.37M0.0012Upcoming EarningsHGASGlobal GasN/A$0.11-8.2%N/A-1.3%$910KN/A0.002Upcoming EarningsGap DownTANHTantech0.9054 of 5 stars$1.98+1.6%N/A-71.9%$190K$42.94M0.0070 Related Companies and Tools Related Companies CARM Competitors TOMZ Competitors ENFY Competitors SNES Competitors GURE Competitors CNEY Competitors NITO Competitors BSLK Competitors HGAS Competitors TANH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
